APM
LXEO icon

Avidity Partners Management’s Lexeo Therapeutics LXEO Stock Holding History

Avidity Partners Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-645,000
Closed -$2.24M – 74
2025
Q1 		$2.24M Buy
+645,000
New +$2.86M 0.43% 55

Other funds holding LXEO

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Avidity Partners Management's LXEO Position: Q2 2025 in Review

Avidity Partners Management sold out of Lexeo Therapeutics (LXEO) in Q2 2025, closing a stake of 645,000 shares — an estimated $2.24M sold.

Avidity Partners Management first reported a position in LXEO in Q1 2025 and held it in 1 quarter. The position peaked at $2.24M in Q1 2025. 90 funds tracked by Wall St. Rank hold LXEO as of Q2 2025.

  • Avidity Partners Management reported no remaining Lexeo Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Avidity Partners Management sold 645,000 Lexeo Therapeutics shares in Q2 2025, an estimated $2.24M.
  • Avidity Partners Management first reported a position in Lexeo Therapeutics in Q1 2025 and held it in 1 quarter.
  • Avidity Partners Management's Lexeo Therapeutics position peaked at $2.24M in Q1 2025.
  • 90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.